Media Center

Share

[Live Webcast May 22] The Impact of GLP-1 Medications

oswaldcompanies May 9, 2024
Share

Join Us as We Discuss the What, Why and How

In 2023, the average cost per claimant for Ozempic® was $5,550, an 18% increase from 2022. Ozempic now ranks as the second highest-paid drug, behind Humira®, according to Unison’s annual book of business report. The number of individuals taking Ozempic increased 135% year-over-year, contributing to the climb in overall healthcare spend*.

According to the CDC, approximately 42% of adult Americans are classified as obese, but this number exceeds 73% when adding in overweight individuals. ​​

Understanding the value of weight loss drugs, potential ROI, treatment plans and wraparound service options are critical as you determine your organizations’ long-term employee benefits strategy.

Join us May 22 as our experienced panel from the Cleveland Clinic and Foundational Pharmacy Strategies discuss these important topics.

Presented by

  • Dr. Bruce Rogen, MD MPH FAC, Chief Medical Officer, Cleveland Clinic
  • Raul J. Rosenthal, MD,FASMBS, Regional Chair, Digestive Disease & Surgical Institute, Department Chair of Bariatric, Metabolic Surgery and General Surgery, Cleveland Clinic
  • Kelly Prymicz, Co-Founder and VP of Clinical Strategy, Foundational Pharmacy Strategies
  • Christine Johnston, Co-Founder and Pharmacy Practice Leader, Foundational Pharmacy Strategies

Moderated by

  • Tom Sigman, Strategic Solutions Leader, Unison Risk Advisors

Wednesday, May 22, 2024 | 10:00 a.m. EST

Register-Button

At Unison Risk Advisors, we create member-driven solutions that help control spend and create quality outcomes. We do this through our Univation Labs team, which is a collaboration of industry experts, academics and clinicians.

*Data source 2022 Unison Risk Advisors book of business.


For more information, contact us here.

Signup